Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 9/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050986 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4KDM1ANPC1RAB9A | |
| SCHEMBL13050949 | 0.87 | OPRM1 (0.47) | NPC1RAB9AOPRM1HPGD | |
| SCHEMBL13050973 | 0.86 | OPRM1 (0.47) | KDM1ANPC1RAB9AOPRM1USP5 | |
| SCHEMBL13050963 | 0.86 | OPRM1 (0.47) | KDM1ANPC1RAB9AOPRM1USP5 | |
| SCHEMBL13050842 | 0.85 | OPRM1 (0.47) | KDM1ANPC1RAB9AOPRM1HPGD | |
| SCHEMBL13050868 | 0.84 | OPRM1 (0.47) | NPC1RAB9AOPRM1HPGD | |
| SCHEMBL13050921 | 0.84 | SLC6A4 (0.50) | SLC6A2SLC6A4NPC1RAB9A | |
| SCHEMBL13050916 | 0.84 | SLC6A4 (0.50) | SLC6A2SLC6A4NPC1RAB9A | |
| SCHEMBL13050888 | 0.84 | OPRM1 (0.47) | NPC1RAB9AOPRM1 | |
| SCHEMBL13050896 | 0.84 | OPRM1 (0.47) | NPC1RAB9AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009036275-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES USING INDATRALINE ANALOGS | LINK MEDICINE CORPORATION (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | SLC6A2 19/4885SLC6A4 44/4885KDM1A 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.